We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Preclinical study demonstrates daily oral SMTC1100 reduces pathology and improves muscle strength in mdx mice, indicating therapeutic potential for clinical trials in Duchenne muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
Tinsley et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: